transaminases in 3 (8.1%) and abdominal pain in 1 (2.7%). Conclusion: In a previous study in the unit, the use of ondansetron, dexamethasone and aprepitant for children with solid tumours receiving high/moderately emetogenic chemotherapy achieved suboptimal control of CINV (complete: 12.5%, good 50%, poor: 37.5%) in 19 consecutive cycles. Poor compliance with the prescribed regimen (42.1%) was possibly related to the high cost of aprepitant (INR 600-1400/kit). Replacing aprepitant with olanzapine (INR 3.26/ 5mg tablet) helped us achieve compliance (100%) and satisfactory control of CINV with minimal toxicity. O-1.20 PREDICTION MODELS IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SYSTEMATIC REVIEW Nita Radhakrishnan. Department of Pediatric Hematology Oncology, Super Speciality Pediatric Hospital and PG Teaching Institute, Gautam Budh Nagar, Noida, 201303, India E-mail address: nitaradhakrishnan@yahoo.com Background: Hemophagocytic Lymphohistiocytosis (HLH) is character- ized by hyperinflammation triggered by infection, malignancies or auto- immunity. HLH is still diagnosed based on criteria that were suggested above a decade back. Various prognostic scores have been evaluated in HLH addressing the disease and its management. In the present study, all the prognostic scores described in HLH were reviewed. Methods: Systematic search of Pubmed/Pubmed-central/ Google-scholar databases were made for studies in children and adults with keywords “hemophagocytic lymphohistiocytosis, hemophagocytosis, prognosis, score/scoring, risk factors and outcome”. All English language articles published till 31th August 2017 were included. All forms of HLH were included. Scoring systems developed by co-operative study groups were not included. Results: >50 studies satisfying the above criteria were identified. They were the further divided into 3 groups; those aiding early diagnosis of HLH, those differentiating familial HLH (FHL) from secondary HLH (sHLH) and those predicting survival. Factors determining survival post bone marrow transplantation were analyzed separately. Those aiding early diagnosis included BM Score (Wang HY, 2014), HS Score(Fardet L, 2014) and H Score (Fardet L, 2014). Criteria used included leukoerythroblastosis, LDH, SGOT in additional to the variables in HLH 2004. MH Score (Minoia F, 2017) used age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and haemoglobin and another score by Lehmberg et al, 2013 attempted to differentiate FHL from sHLH. Studies addressing prognosis in HLH were published mainly between 2014-2017 and had samples ranging from 5- 300 subjects. Aggressive clinical phenotype, CNS involvement, degree of coagulopathy, hyperferritinemia, malignancy, IL-10, IFN etc. were some factors identified on multivariate regression analysis. Conclusion: Multiple scores have been developed to address the various ambiguities of the disease. The need of the hour would be a collaborative data on the disease profile and biomarkers at onset that can give better discriminative and prognostic information. O-1.21 ESTABLISHMENT OF A BIOREPOSITORY OF PAEDIATRIC CANCERS: THE TATA MEDICAL CENTER EXPERIENCE Arindam Basu a, e,f , Debparna Saha a, e, f , Rubina Islam a, e,f , Arunabha Chakrabarti a, e, f , Anindita Dutta a, e, f , Meghna Banerjee a, b, e, f , Pritha Paul a, e, f , Sriparna Sadhukhan a, e, f , Sriparna Giri c, e, f , Shyamashree Biswas d, e, f , Mou Das a, e, f , Prakriti Roy a, e,f , Sudeshna Dhar a,e, f , Vaskar Saha a, c, e,f , Debdutta Ganguli a, e, f , Usha Menon d, e, f , Shekhar Krishnan a, e, f . a Tata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India; b Nilratan Sircar Medical College, Kolkata, India; c Nursing, Tata Medical Center, Kolkata, India; d Customer Care, Tata Medical Center, Kolkata, India; e Division of Cancer Sciences, University of Manchester, Manchester, UK; f University College London, London, UK Supported in part by the Tata Medical Center Kolkata and Wellcome-DBT India Alliance. Background: A fundamental prerequisite of bench-to-bedside studies is the availability of banked biological samples. At the Tata Medical Center (TMC), standardised ethics-approved processes have been developed to ensure systematic banking of high quality, appropriately consented clinical material. This biorepository is linked to standardised clinical studies, providing a powerful platform for investigating disease and its treatment and the translation of these findings to the clinic. Over the past 3 years, samples have been banked serially from paediatric patients with haema- tological malignancies treated on standardised protocols. Methods: Following due consent, pseudoanonymised excess clinical samples (blood, marrow, body fluids, tissue) were collected serially for banking. Sampling timepoints coincide with scheduled clinical proced- ures. Diagnostic and follow-up peripheral blood (PB) and bone marrow (BM) samples in EDTA were processed using standardised protocols, to generate plasma and mononuclear cell (MNC) fractions. Following enumeration, MNCs were cryopreserved or stored frozen as dried pellets for generating lysates. Clinical and diagnostic laboratory annotation of banked samples is accomplished by linking the biobank Laboratory In- formation System with TMC’s Hospital Management System. Downstream analyses on banked samples were performed as part of IRB-approved studies. Processing procedures are reviewed continually to improve yield and quality and adapted frequently to meet evolving study requirements. Results: Over 3 years, 2356 samples were banked from 455 patients (mean, ~5 samples/patient), including diagnostic and follow-up BM, PB and cerebrospinal fluid samples (34%, 61%, 5% respectively). An average 13.5 microgram DNA was isolated from MNC pellets (~60% of projected DNA yield), of suitable quality for quantitative PCR, DNA arrays and high- throughput sequencing studies. Banked plasma samples (n¼128) have been successfully tested for Asparaginase activity. The average post-thaw viability of cryopreserved samples is 60%. Conclusions: Our experience provides insights for the creation of similar biobanks across India as a networked national resource for paediatric cancers. O-1.22 THE ROLE OF ZINC AND FOLIC ACID SUPPLEMENTATION AS AN AID TO HEMATOLOGICAL RECOVERY IN DENGUE FEVER Amulya Manohar, A.T.K. Rau, Vanitha Gowda Radhika. Ramaiah Medical College, Bangalore, India Aim: To assess baseline serum levels of zinc and folic acid in children with dengue fever and to supplement these micronutrients at standard dosages with the aim to assess their role in hematological recovery, progression to severe dengue, mortality (if any) and duration of hospital stay. Material and methods: 165 consecutive paediatric patients admitted to our tertiary care hospital were clinically studied in detail, the findings recorded on a proforma, and then randomly allocated to one of three equal groups using random number table - Group 1 / Group 2/ Group 3 who were supplemented with Folic acid, Zinc and no supplementation respectively. 5ml of blood was collected soon after admission with due aseptic pre- cautions in plain vacutainer tubes and after extracting the serum in the diagnostic laboratory of our tertiary care teaching hospital were stored at -80C. Serum Zinc was estimated using a colorimetric kit procured from Coral Clinical Systems on a colorimeter in the Department of Biochemistry of the teaching institution. The reference range: 80-120mcg/dl. Serum Folic acid was estimated by ELISA method using a kit procured from Bio- vendor Group on the ELISA Reader in the Central Research Laboratory of the teaching hospital. The reference range: 6-20ng/ml.Supplementation of micronutrient began within 24 hours of receipt of dengue sero-positivity report and after sending serum for zinc/folic acid estimation in the respective groups. Results: Supplementation of zinc or folic acid reduces the number of days for reversal of declining platelet counts in DHF. Folate supplementation yielded better results. The progression to severe disease (DSS) was also lesser with supplementation of either of these nutrients (folate 29%, zinc 38%) compared to the control group (58%). On supplementing folic acid or zinc, the mean duration of stay in the hospital was lessened by a day or more, compared to the control group. Again, folic acid supplementation yielded slightly better results compared to zinc in this regard. Children who were pre-illness deficient in folic acid or zinc had higher propensity to develop fluid refractory shock and eventually needed more inotropic support compared to the non-deficient individuals. Abstracts / Pediatric Hematology Oncology Journal 2 (2017) S1eS8 S7